The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preliminary results of a phase I trial of FT516, an off-the-shelf natural killer (NK) cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line expressing high-affinity, non-cleavable CD16 (hnCD16), in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL).
 
Paolo Strati
Consulting or Advisory Role - Genentech/Roche
Research Funding - AstraZeneca
 
Veronika Bachanova
Consulting or Advisory Role - Karyopharm Therapeutics; Karyopharm Therapeutics; Kite, a Gilead company; Seagen
Research Funding - Celgene (Inst); Gamida Cell; Incyte; Novartis (Inst)
 
Aaron Goodman
Honoraria - Seagen
Consulting or Advisory Role - Seagen
Speakers' Bureau - Seagen
Travel, Accommodations, Expenses - Seagen
 
John M. Pagel
Consulting or Advisory Role - Actinium Pharmaceuticals; AstraZeneca; BeiGene; Epizyme; Gilead Sciences; Loxo; MEI Pharma; MorphoSys; TG Therapeutics
 
Januario E. Castro
No Relationships to Disclose
 
Kelly Griffis
Employment - Fate Therapeutics
Stock and Other Ownership Interests - Fate Therapeutics
 
Marlisa Anderson
No Relationships to Disclose
 
Siminder K. Atwal
Employment - Fate Therapeutics
Stock and Other Ownership Interests - BeiGene; Fate Therapeutics
 
Cara Bickers
Employment - Fate Therapeutics
Stock and Other Ownership Interests - Fate Therapeutics
 
Daniel Fremgen
Employment - Fate Therapeutics
 
Christina Ly
Employment - Fate Therapeutics
 
Sarah A. Cooley
Employment - Fate Therapeutics
 
Rebecca L. Elstrom
Employment - BeiGene; Fate Therapeutics
Stock and Other Ownership Interests - BeiGene; Roche/Genentech
 
Krish Patel
Consulting or Advisory Role - AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene/Juno; Genentech; Kite, a Gilead company; Morphosys; Pharmacyclics; TG Therapeutics
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb/Celgene; Genentech; Kite, a Gilead company; Pharmacyclics/Janssen; TG Therapeutics
Research Funding - Aptevo Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Curis (Inst); Fate Therapeutics (Inst); Kite/Gilead (Inst); MEI Pharma (Inst); Pharmacyclics (Inst); Roche/Genentech (Inst); Sunesis Pharmaceuticals (Inst); Takeda (Inst); Trillium Therapeutics (Inst); Xencor (Inst)